(February 4, 2014) In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy. The work … Continued
(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer. The … Continued
(Feb. 2, 2015) Recent studies have suggested that ovarian cancer predominantly arises within the fallopian tubes or the uterus. A group of Swedish researchers hypothesized that surgical removal of the fallopian … Continued
A year after her diagnosis with ovarian cancer in May 2011, Dr. Jan Byrne began looking for ways to be more involved in ovarian cancer advocacy and education. She connected … Continued
(January 28, 2015) OCRF grantee Ron Chandler, PhD developed a mouse model of clear cell ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Dr. … Continued
(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment … Continued
(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to … Continued
The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will … Continued
A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative … Continued
Starting the new year with a mission to fund ovarian cancer research Friday, January 2nd, 2015 – New York, NY Amrita Singh Jewelry is proud to announce a new initiative … Continued
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly … Continued
When Diane Riche’s mother was diagnosed with ovarian cancer in 2010, Diane turned to the internet for information. Through her research she came to the Alliance’s website, where she learned … Continued
Get email updates about research news, action alerts, and ways to join the fight.
